HPTN Publications

El-Sadr WM, Affrunti M, Gamble T, Zerbe A . Antiretroviral therapy: a promising HIV prevention strategy?. J Acquir Immune Defic Syndr. 2010, 55: 116-21

El-Sadr WM, Beauchamp G, Hall IH, Torian LV, Zingman BS, Lum G, Elion RA, Buchacz K, Burns D, Zerbe A, Gamble T, Donnell D, for the HPTN 065 Study Team . Durability of the Effect of Financial Incentives on HIV Viral Load Suppression and Continuity in Care. JAIDS.

El-Sadr WM, Mayer KH, Maslankowski L, Hoesley C, Justman J, Gai F, Mauck C, Absalon J, Morrow K, Masse B, Soto-Torres L, Kwiecien A and the HPTN 049 Team . Safety and acceptability of cellulose sulfate as a vaginal microbicide in HIV-infected women. AIDS. 2006, 20: 1109-16 PMID: 16691061

El-Sadr WM, Serwadda DM, Sista N, Cohen MS . HIV prevention: great achievements, more challenges ahead. J Acquir Immune Defic Syndr. 2013, 63: S115-6

Elizabeth Greene . Testing a Culturally Responsive Intersectional Stigma Prevention Approach for Black MSM with Healthcare Facilities in the US South: The HPTN 096 CRISP Intervention.

Emory JF, Seserko LA, Marzinke MA . Development and bioanalytical validation of a liquid chromatographic-tandem mass spectrometric (LC-MS/MS) method for the quantification of the CCR5 antagonist maraviroc in human plasma. Clin Chim Acta. 2014, Apr 20: 198-205

Eshleman SH, Becker-Pergola G, Deseyve M, Guay LA, Mracna M, Fleming T, Cunningham S, Musoke P, Mmiro F, Jackson JB . Impact of human immunodeficiency virus type 1 (hiv-1) subtype on women receiving single-dose nevirapine prophylaxis to prevent hiv-1 vertical transmission (hiv network for prevention trials 012 study). J Infect Dis. 2001, 184: 914-7

Eshleman SH, Church JD, Chen S, Guay LA, Mwatha A, Fiscus SA, Mmiro F, Musoke P, Kumwenda N, Jackson JB, Taha TE, Hoover DR . Comparison of HIV-1 mother-to-child transmission after single-dose nevirapine prophylaxis among African women with subtypes A, C, and D. J Acquir Immune Defic Syndr. 2006, 42: 518-21 PMID 16810119